Is the Customer Always Right? Department of Health and Human Services’ Proposed Regulations Allow Institutional Review Boards to Place Customer Service Ahead of the Welfare of Research Participants by Zern, Colleen O\u27Hare
Saint Louis University Public Law Review 
Volume 32 
Number 2 General Issue (Volume XXXII, No. 2) Article 8 
2013 
Is the Customer Always Right? Department of Health and Human 
Services’ Proposed Regulations Allow Institutional Review Boards 
to Place Customer Service Ahead of the Welfare of Research 
Participants 
Colleen O'Hare Zern 
czern2@slu.edu 
Follow this and additional works at: https://scholarship.law.slu.edu/plr 
 Part of the Law Commons 
Recommended Citation 
Zern, Colleen O'Hare (2013) "Is the Customer Always Right? Department of Health and Human Services’ 
Proposed Regulations Allow Institutional Review Boards to Place Customer Service Ahead of the Welfare 
of Research Participants," Saint Louis University Public Law Review: Vol. 32 : No. 2 , Article 8. 
Available at: https://scholarship.law.slu.edu/plr/vol32/iss2/8 
This Comment is brought to you for free and open access by Scholarship Commons. It has been accepted for 
inclusion in Saint Louis University Public Law Review by an authorized editor of Scholarship Commons. For more 
information, please contact Susie Lee. 
SAINT LOUIS UNIVERSITY SCHOOL OF LAW 
 
411 
IS THE CUSTOMER ALWAYS RIGHT? DEPARTMENT OF HEALTH 
AND HUMAN SERVICES’ PROPOSED REGULATIONS ALLOW 
INSTITUTIONAL REVIEW BOARDS TO PLACE CUSTOMER 
SERVICE AHEAD OF THE WELFARE OF RESEARCH 
PARTICIPANTS 
INTRODUCTION 
“[C]oast through your next study.”1 Coast Institutional Review Board 
(IRB), a for-profit company, offered a coupon, including this statement 
informing potential customers that they could “coast” through any study 
review, on its website for a free IRB review of a research protocol.2 True to its 
word, Coast IRB allowed customers to coast through IRB review.3 In 2009, 
Coast IRB unanimously approved a study involving a fictitious medical 
product from a fictitious investigator at a fictitious company.4 This bogus 
medical product was derived from a real product that the Food and Drug 
Administration (FDA) pulled from the market after it killed human research-
subjects.5 In fact, two other IRBs rejected the fictitious study, while claiming 
that the study was “the worst thing I have ever seen” and was “a terrible risk 
for the patient.”6 In August 2011, just two years after the Coast IRB incident, 
Essex IRB fell into a similar trap.7 Essex IRB, another for-profit IRB, 
 
 1. Coast Institutional Review Board’s coupon enticed customers to use its services by 
implying its review of the study will be easy for the customer. Institutional Review Boards That 
Oversee Experimental Human Testing for Profit: Hearing Before the Subcomm. on Oversight and 
Investigations of the Comm. on Energy and Commerce, 111th Cong. 2–3 (2009) [hereinafter 
Hearing on IRBs] (statement of Rep. Bart Stupak, Chairman, Comm. on Energy and Commerce). 
This hearing has not been discussed in any legal journal articles regarding IRBs. 
 2. Id. 
 3. See e.g., Alicia Mundy, Sting Operation Exposes Gaps in Oversight of Human 
Experiments, WALL ST. J. (Mar. 26, 2009), http://online.wsj.com/article/SB1238111795723531 
81.html. 
 4. See id. 
 5. Hearing on IRBs, supra note 1, at 2 (statement of Rep. Bart Stupak, Chairman, Comm. 
on Energy and Commerce). 
 6. Id. 
 7. Inspectional Observations, U.S. Dep’t of Health and Human Servs. Food & Drug 
Admin., Form FDA 483 (Mar. 14–21, 2011), http://www.circare.org/fdawls/essexirb_fdafoia_ 
2011-6068.pdf. 
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approved a similar bogus study using the same fictitious investigator from the 
2009 sting operation.8 
IRBs are the formal entities, regulated by the Department of Health and 
Human Services (HHS), responsible for reviewing research involving human 
subjects.9 All federally funded human subjects research and all FDA regulated 
studies must be approved by an IRB.10 An IRB’s primary purpose is to “protect 
the rights and welfare of human research subjects” by approving, modifying, or 
rejecting human research studies.11 IRBs have a duty to assure research-
subjects that all study risks are fully disclosed, that all risks will be minimized 
to the extent possible, and that all risks are appropriate in relation to any 
anticipated benefits.12 
Originally, the Office for Protection from Research Risks (OPRR) allowed 
only IRBs located in or supported by institutions to review federally funded 
studies.13 These institutionally supported IRBs, composed primarily of 
members from the research institution, are referred to as “local IRBs.”14 
Subsequently, in 1996, OPRR changed its position to allow IRBs that are 
unaffiliated with the institution engaged in research to review federally funded 
studies.15 These unaffiliated IRBs are referred to as “independent IRBs.”16 
Currently, the Office of Human Research Protections (OHRP)—which 
replaced OPRR in 200017—allows an institution to choose whether to use its 
local IRB or to rely on the review of another, qualified IRB.18 However, on 
July 26, 2011, HHS and the Office of Science and Technology Policy (OSTP) 
issued proposed regulations for “Streamlining IRB Review of Multi-Site 
Studies,” which suggest mandating a central IRB for multi-site studies in order 
to strengthen protection for research subjects.19 A “central IRB” is a single IRB 
 
 8. Id. 
 9. U.S. DEP’T OF HEALTH & HUMAN SERVS., Chapter 1: Institutional Administration, in 
INSTITUTIONAL REVIEW BOARD GUIDEBOOK 1 (1993), available at http://www.hhs.gov/ohrp/ar 
chive/irb/irb_chapter1.htm. 
 10. Human Subjects Research Protections, 76 Fed. Reg. 44,512, 44,512–13 (proposed July 
26, 2011); Institutional Review Boards, 21 C.F.R. § 56.103(a) (2012). 
 11. U.S. DEP’T OF HEALTH & HUMAN SERVS., supra note 9, at 1. 
 12. U.S. DEP’T OF HEALTH & HUMAN SERVS., Chapter 3: Basic IRB Review, in 
INSTITUTIONAL REVIEW BOARD GUIDEBOOK, supra note 9, at 2. 
 13. David Forster, Independent Institutional Review Boards, 32 SETON HALL L. REV. 513, 
517 (2002). 
 14. Id. at 515. 
 15. Id. at 517–18. 
 16. Id. 
 17. Office of Public Health and Science, 65 Fed. Reg. 37,136 (June 13, 2000). 
 18. Protection of Human Subjects, 45 C.F.R. § 46.114 (2011). 
 19. Human Subjects Research Protections, 76 Fed. Reg. 44,512, 44,512, 44,521 (proposed 
July 26, 2011). The proposed regulations cover seven topics: “Ensuring Risk-Based Protections, 
Streamlining IRB Review of Multi-Site Studies, Improving Informed Consent, Strengthening 
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that reviews a study that will take place at multiple research sites and whose 
review will supplant the local IRB’s review on the study.20 
This note will argue, by analyzing the proposed regulations and their 
implications for research-subjects’ protection, that forcing a research site to use 
a central IRB does not strengthen protection for research subjects.21 Due to the 
challenges imposed on a local IRB to approve and monitor the many 
institutions in a multi-site study, these proposed regulations are effectively 
forcing institutions to use an independent IRB.22 Since the majority of 
independent IRBs are for-profit IRBs,23 these regulations will push IRB review 
to for-profit companies, companies like Coast IRB and Essex IRB. For-profit 
IRBs do not operate in the best interests of the research subjects because they 
have greater incentives, namely income, to approve research proposals, as 
illustrated in the Coast IRB and Essex IRB cases.24 Additionally, for-profit 
IRBs have a conflict of interest because their sole source of income is the fees 
paid by the sponsors, the companies backing the study, writing the research 
protocol, and investing in this protocol’s approval.25 As a result, under the 
proposed regulations, research subjects face a greater risk of participating in 
potentially harmful studies.26 
 
Data Protections to Minimize Information Risks, Data Collection to Enhance System Oversight, 
Extension of Federal Regulations, and Clarifying and Harmonizing Regulatory Requirements and 
Agency Guidance.” Id. at 44,512. 
 20. Id. at 44,522. 
 21. This note will focus on biomedical and pharmaceutical clinical trials. Distinguishing 
between biomedical and behavioral research is necessary in order to know which activities need 
to be reviewed. THE NAT’L COMM’N FOR THE PROT. OF HUMAN SUBJECTS OF BIOMEDICAL AND 
BEHAVIORAL RESEARCH, THE BELMONT REPORT 10 (1979), available at http://www.fda.gov/ohr 
ms/dockets/ac/05/briefing/2005-4178b_09_02_Belmont%20Report.pdf (stating “problems 
relating to social experimentation may differ substantially from those of biomedical and 
behavioral research”). Additionally, social scientists see social science research as fitting poorly 
into the “medically-driven IRB protocol templates and language.” Caroline H. Bledsoe et al., 
Regulating Creativity: Research and Survival in the IRB Iron Cage, 101 NW. U. L. REV. 593, 
596–97 (2007). Furthermore, FDA regulation of devices requires the use of local institutional 
review committees in the same facilities as where the testing of the device is to occur. See also 
Human Subjects Research Protections, 76 Fed. Reg. 44,512, 44,521 (proposed July 26, 2011) 
(stating that the proposed regulations not apply to FDA-regulated device studies). Therefore, this 
analysis does not pertain to behavioral research or medical device research. 
 22. See infra text accompany notes 133–63. 
 23. Compare Ruth Macklin, How Independent Are IRBs?, IRB: ETHICS & HUMAN 
RESEARCH, May–June 2008, at 15, 19 (2008) (stating that there are some not for profit 
independent IRBs, but that information on them is scarce), with Commercial Institutional Review 
Boards, CITIZENS FOR RESPONSIBLE CARE AND RESEARCH, http://www.circare.org/info/commer 
cialirb.htm (last visited Apr. 19, 2013) (listing forty-nine active commercial IRBs). 
 24. See infra text accompanying notes 221–42. 
 25. See infra text accompanying notes 221–32. 
 26. See infra text accompanying notes 213–45. 
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The first section examines the history of research-subjects’ protection, the 
proposed regulations, and the current legal issues involving IRB review. The 
second section explains why the proposed regulations will essentially push 
IRB review to independent IRBs and why independent IRBs do not act in the 
research-subjects’ best interests. The final section makes suggestions for 
improving research-subjects protection if the ultimate HHS regulations include 
this central IRB provision. 
I.  UNDERSTANDING INSTITUTIONAL REVIEW BOARDS AND THE PROPOSED 
REGULATIONS 
A. History of Regulating Research-Subjects’ Protection 
Both the International community and the United States developed 
regulations to protect research subjects in response to subject abuse in 
“scientific” experiments. The Nuremberg Code, which was enacted in 1949 in 
response to Nazi experimentation on concentration camp prisoners,27 
developed the basic principles of ethical conduct for research involving human 
subjects and specified ten “Directives for Human Experimentation.”28 In 1964, 
the World Medical Association adopted similar recommendations in the 
Declaration of Helsinki.29 Among other requirements, the Declaration of 
Helsinki mandates that research ethics committees be “independent of the 
researcher, the sponsor, and any other undue influences.”30 Although the 
United States adopted many of these directives when creating its own research-
subjects’ protection regulations,31 the United States has not expressly adopted 
 
 27. Human Subjects Research Protections, 76 Fed. Reg. 44,512, 44,512 (proposed July 26, 
2011); THE NAT’L COMM’N FOR THE PROT. OF HUMAN SUBJECTS OF BIOMEDICAL AND 
BEHAVIORAL RESEARCH, supra note 21, at 2. 
 28. Human Subjects Research Protections, 76 Fed. Reg. 44,512, 44,512 (proposed July 26, 
2011); The Nuremberg Code, NATIONAL INSTITUTES OF HEALTH, available at http://history.nih. 
gov/research/downloads/nuremberg.pdf. The ten directives mandate voluntary consent, 
experiments be for the good of society, experiments have anticipated results that justify the 
performance, experiments that avoid unnecessary physical and mental pain, experiments that will 
not knowingly result in subject death or disabling injury, experiments whose importance 
outweighs risks to subjects, protection against remote possibilities of injury or death, experiments 
conducted only by qualified personnel, subject autonomy to end a study at any point, and scientist 
agreement to terminate an experiment if it is likely to result in injury, disability, or death of the 
subject. Id. 
 29. Human Subjects Research Protections, 76 Fed. Reg. 44,512, 44,512 (proposed July 26, 
2011). 
 30. World Medical Association Declaration of Helsinki: Ethical Principles for Medical 
Research Involving Humans, WORLD MEDICAL ASSOCIATION, para. 15, http://www.wma.net/en/ 
30publications/10policies/b3/17c.pdf (last visited Apr. 19, 2013). 
 31. Compare The Nuremberg Code, supra note 28 (requiring voluntary consent and 
continued observation after initial approval), with Protection of Human Subjects, 45 C.F.R. § 
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all of the provisions of the Nuremberg Code and the Declaration of Helsinki.32 
Furthermore, United States courts have varied in their application of the 
Nuremberg Code to cases involving injured research subjects.33 In contrast, 
courts have consistently concluded that the Declaration of Helsinki does not 
apply in the United States.34 
Before the United States developed its own research-subjects’ protection 
regulations, astounding research abuses occurred on United States soil: 
deliberately denying treatment to men with syphilis,35 injecting plutonium into 
unsuspecting hospital patients,36 purposefully infecting children with 
 
46.116 (2011) (mandating subject’s legally effective informed consent for subject’s involvement 
in research experiment), and Protection of Human Subjects, 45 C.F.R. § 46.109(e) (2011) 
(requiring continuing review of a study at least once a year). 
 32. Compare The Nuremberg Code, supra note 28 (necessitating the risk to never exceed the 
humanitarian importance of the problem to be solved by the experiment), and World Medical 
Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Humans, 
supra note 30, para. 24 (requiring subjects be adequately informed of sources of funding, any 
possible conflicts of interest, and any other relevant aspects of the study), with Protection of 
Human Subjects, 45 C.F.R. § 46.101 (2011). 
 33. Compare Grimes v. Kennedy Krieger Inst., Inc., 782 A.2d 807, 835 (Md. Ct. App. 2001) 
(finding the Nuremberg Code to be the “most complete and authoritative statement of the law of 
informed consent to human experimentation” and that “absence of judicial precedent makes 
codes, especially judicially-crafted codes like the Nuremberg Code, all the more important”), with 
Robertson v. McGee, No. 01-CV-60-C, 2002 U.S. Dist. LEXIS 4072, at *9 (D. Okla. Jan. 28, 
2002) (stating that the court agrees that there is “no private right of action for an alleged violation 
of international law” under the Nuremberg Code). Resorting to international law is unnecessary 
when there is a standard in the Code of Federal Regulations. Id. at *9–*10. 
 34. Sykes v. United States, No. 1:10-CV-688, 2011 U.S. Dist. LEXIS 94815, at *9, *45 (D. 
Ohio July 22, 2011) (holding that there was no private right of action for alleged violation of the 
Helsinki Declaration in a case where a human subject allegedly died from pharmaceuticals given 
in a clinical trial because the Code of Federal Regulations governs human subjects research in the 
United States). See also White v. Paulsen, 997 F. Supp. 1380, 1383 (D. Wash. 1998); Hoover v. 
West Virginia Dep’t. of Health & Human Services, 984 F. Supp. 978, 980 (D. W.Va. 1997); 
Abdullahi v. Pfizer, Inc., No. 01 Civ. 8118, 2005 U.S. Dist. LEXIS 16126, at *31 (D. N.Y. Aug. 
09, 2005). 
 35. From 1932-1972, the United States Public Health Service documented the natural history 
of syphilis, using 399 black sharecroppers infected with syphilis, in the Tuskegee Syphilis Study. 
CARL H. COLEMAN ET AL., THE ETHICS AND REGULATION OF RESEARCH WITH HUMAN 
SUBJECTS 41 (2005). Not only did the physicians deny treatment to the men with syphilis, even 
after the effective treatment of penicillin became available, but they also went to “extreme lengths 
to ensure that they would not receive therapy from other sources.” Id. at 41. 
 36. From 1944–1974, the federal government funded radiation experiments where 
physicians “inject[ed] plutonium into unsuspecting hospital patients” and released radiation into 
the environment. Id. at 44. Several patients died from acute radiation effects. Id. In addition, the 
government did not maintain adequate records in order to keep the public from learning about 
these programs. Id. at 45. 
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hepatitis,37 and injecting live cancer cells into elderly patients.38 Following 
these highly publicized cases of research abuse, United States federal agencies 
enacted the 1974 Research Act.39 In 1979, the National Commission published 
its own guidelines for research-subjects’ protection in the Belmont Report.40 
The Belmont Report provided a framework to guide the resolution of ethical 
problems arising in human-subjects’ research.41 In addition to the Belmont 
Report, in 1981, the FDA created provisions requiring IRB approval during the 
FDA clinical investigation procedure, which include IRB review of clinical 
investigations and of continuing review.42 Continuing review is the process of 
periodically reviewing a study after the initial approval.43 Subsequently, in 
1991, fourteen federal departments joined with HHS to adopt uniform rules, 
known as the Common Rule, for the protection of research subjects.44 The 
Common Rule covers all federally conducted or supported human-subjects 
research.45 
The Common Rule documents IRB member requirements: a minimum of 
five members with varying backgrounds, a minimum of one member with a 
primary scientific area of concern, a minimum of one member with a primary 
nonscientific area of concern, and a minimum of one member not affiliated 
with the institution.46 The Common Rule requires IRB member diversification 
in order for its members to have sufficient experience and expertise to 
 
 37. From 1956–1971, Doctor Saul Krugman “fed extracts of stools from [hepatitis] infected 
[institutionalized] children” as well as injected children with the hepatitis virus in order to study 
the hepatitis virus. Id. at 39. 
 38. In 1963, the NIH and the Public Health Service funded a study where physicians 
“injected live cancer cells into twenty-two indigent, chronically ill, and debilitated [and 
unsuspecting] elderly patients at the Brooklyn Jewish Chronic Disease Hospital.” Id. at 39. 
 39. Human Subjects Research Protections, 76 Fed. Reg. 44,512, 44,512 (proposed July 26, 
2011). This Act created the National Commission for the Protection of Human Subjects of 
Biomedical and Behavioral Research (National Commission). Id. 
 40. Id. 
 41. THE NAT’L COMM’N FOR THE PROT. OF HUMAN SUBJECTS OF BIOMEDICAL AND 
BEHAVIORAL RESEARCH, supra note 21, at 3. 
 42. Protection of Human Subjects, 46 Fed. Reg. 8,958 (January 27, 1981) (codified at 21 
C.F.R. § 56.101); 21 C.F.R. § 56.103(a) (2012). 
 43. 21 C.F.R. § 56.103(a) (2012). 
 44. Human Subjects Research Protections, 76 Fed. Reg. 44,512, 44,512 (proposed July 26, 
2011). The Common Rule adopted 45 C.F.R. Part 46 Subpart A of the HHS regulations. Id. A 
total of seventeen federal agencies now follow some form of the Common Rule. U.S. GOV’T 
ACCOUNTABILITY OFFICE, GAO-09-448T, HUMAN SUBJECTS RESEARCH: UNDERCOVER TESTS 
SHOW THE INSTITUTIONAL REVIEW BOARD SYSTEM IS VULNERABLE TO UNETHICAL 
MANIPULATION 6 (2009). 
 45. Protection of Human Subjects, 45 C.F.R. § 46.101(a) (2011). 
 46. 45 C.F.R. § 46.107(a), (c), (d). The FDA’s IRB member requirements match those of the 
Common Rule. See Institutional Review Boards, 21 C.F.R. § 56.107 (2012). 
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safeguard the rights and welfare of research subjects.47 Additionally, the 
Common Rule mandates that IRBs provide continued review of studies at least 
once per year.48 The last major addition to research-subjects’ regulations came 
in 2009 when HHS required each IRB reviewing research conducted or 
supported by HHS to be registered with HHS.49 
B. Proposed Regulations: “Enhancing Protection for Research Subjects and 
Reducing Burden, Delay, and Ambiguity for Investigators” 
When the current regulations were developed, research generally took 
place at single sites, predominantly universities, colleges, and medical 
institutions.50 Presently, however, a substantial portion of research occurs in 
multi-site studies at centers unaffiliated with these academic research 
institutions.51 Multi-site studies, studies where a single research protocol is 
conducted at numerous research sites, are particularly common in clinical 
trials.52 This change in research dynamics is partially due to the shift in clinical 
trial funding from the government to pharmaceutical companies53 and to the 
need of these trials to generate sufficient participant numbers and generalizable 
results.54 Research-subjects’ protection regulations, on the other hand, have not 
evolved along with the proliferation of multi-site clinical trials.55 While the 
Common Rule does not require separate approval from every local IRB in a 
multi-site study, in many of these studies each institution’s local IRB will 
review the research protocol independently, resulting in duplicative reviews of 
 
 47. Protection of Human Subjects, 45 C.F.R. § 46.103(b)(3) (2011). 
 48. 45 C.F.R. § 46.109(e). The IRB has the discretion to determine the frequency of 
continuing review. Id. However, in determining this frequency, the IRB is to consider the degree 
of risk. Id. 
 49. 45 C.F.R. § 46.501. This registration must be renewed every three years. Id. at § 
46.505(a). 
 50. Human Subjects Research Protections, 76 Fed. Reg. 44,512, 44,512 (proposed July 26, 
2011). 
 51. Id. at 44,521; Trudo Lemmens & Benjamin Freedman, Ethics Review for Sale? Conflict 
of Interest and Commercial Research Review Boards, 78 MILBANK Q. 547, 548–49 (2000) 
(stating that research of new drugs is increasingly taking place at pharmaceutical research centers 
or physicians’ offices independent of academic research centers). 
 52. Human Subjects Research Protections, 76 Fed. Reg. 44,512, 44,521 (proposed July 26, 
2011). 
 53. Lynn A. Jansen, Local IRBs, Multicenter Trials, and the Ethics of Internal Amendments, 
27 IRB: ETHICS & HUM. RES. 7, 7 (2005). 
 54. William Burman & Robert Daum, Grinding to a Halt: The Effects of the Increasing 
Regulatory Burden on Research and Quality Improvement Efforts, 49 CLINICAL INFECTIOUS 
DISEASES 328, 330 (2009). 
 55. Human Subjects Research Protections, 76 Fed. Reg. 44,512, 44,512 (proposed July 26, 
2011). 
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study protocols.56 Further delaying the research process, investigators must 
resubmit any IRB protocol changes made by a local IRB to all reviewing 
IRBs.57 For these reasons, critics have argued that the highly regulated IRB 
review structure hinders the research process by creating inefficiencies and 
adding bureaucratic complexity with duplicative IRB review.58 These critics 
have claimed that research is unnecessarily delayed, since there is no evidence 
that research subjects are protected by the multiple reviews.59 Conversely, the 
absence of evidence, especially in the absence of any research focusing on the 
safety of these reviews, is not a reasonable argument to change regulations. 
Duplicative reviews of studies provide additional scrutiny of research protocols 
for the primary goal of protecting research subjects. Until more research is 
performed, there is no evidence to demonstrate that removal of these additional 
reviews will benefit research subjects. However, in response to the critics, 
HHS proposed new human subjects research protection regulations.60 
1. Proposed Regulations 
On July 26, 2011, HHS and OSTP proposed regulations to strengthen 
protection for research subjects and to match the “evolving human research 
enterprise [and] the proliferation of multi-site clinical trials.”61 HHS and OSTP 
requested comments to the proposed regulations be submitted before October 
26, 2011.62 As of the date of this note, the proposed regulations are closed for 
commenting, and HHS has yet to release final regulations.63 
The proposed regulations mandate “that all domestic sites in a multi-site 
study rely upon a single IRB as their IRB of record for that study,”64 meaning 
the regulations require the use of a central IRB for multi-site studies. This is a 
change from the current regulations, which give institutions a choice in 
 
 56. Id. at 44,521, 44,522. 
 57. Id. 
 58. Id. at 44,513. 
 59. Id. 
 60. Id. at 44,512. 
 61. Human Subjects Research Protections, 76 Fed. Reg. 44,512, 44,512 (proposed July 26, 
2011). 
 62. Initial comment deadline was September 26, 2011. Human Subjects Research 
Protections, 76 Fed. Reg. 44,512, 44,512 (proposed July 26, 2011). HHS and OSTP extended the 
deadline to October 26, 2011 after multiple requests for extensions. Advanced Notice of Public 
Rule Making, U.S. DEP’T OF HEALTH & HUMAN SERVS., http://www.hhs.gov/ohrp/humansub 
jects/index.html (last visited Apr. 19, 2013). 
 63. Information Related to Advanced Notice of Proposed Rulemaking (ANPRM) for 
Revisions to the Common Rule, U.S. DEP’T OF HEALTH & HUMAN SERVS., http://www.hhs.gov/ 
ohrp/humansubjects/anprm2011page.html (last visited Apr. 19, 2013). 
 64. Human Subjects Research Protections, 76 Fed. Reg. 44,512, 44,522 (proposed July 26, 
2011). 
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deciding whether to use a central IRB or their own IRB in multi-site studies.65 
The regulations do not suggest guidelines for how to select the IRB of record, 
but the regulations seemingly give the sponsor unfettered discretion to choose 
the IRB of record for multi-site studies.66 Complete sponsor discretion poses a 
serious concern for research-subjects’ interests, since research subjects place 
trust in an unbiased IRB to protect their welfare. Additionally, while local sites 
would not be relieved of any obligations under the research-subjects’ 
protection regulations, local internal reviews could be discouraged and would 
not have regulatory status with the Common Rule under the proposed 
regulations.67 Therefore, local IRB review may be limited, if at all necessary, 
to perspectives of the local community:68 cultural backgrounds of the research 
subjects’ population, community attitudes about the proposed research, and the 
capacity of the institution to support the proposed research.69 However, even 
this review may be limited as the proposed regulations suggest, in contrast to 
previous regulations, that “[t]he evaluation of a study’s social value, scientific 
validity, and risks and benefits, and the adequacy of the informed consent 
document and process generally do not require the unique perspective of a 
local IRB.”70 
2. HHS Support for Proposed Regulations 
In addition to HHS and OSTP opinions on the need for central IRB review 
of multi-site studies, the proposed regulations cited recent academic journal 
articles in support of the new regulations. These studies highlight concerns 
with research integrity, site-specific modifications, and variability among local 
IRB review.71 Multiple reviews of multi-site studies can affect research 
integrity when IRB reviews produce different outcomes for identical studies.72 
 
 65. Id. 
 66. Id. at 44,521–22. See also Janet M. Lis & Melina G. Murray, The Ins and Outs of 
Independent IRBs, 2 J. HEALTH & LIFE SCI. 73, 79 (2008). 
 67. Human Subjects Research Protections, 76 Fed. Reg. 44,512, 44,522 (proposed July 26, 
2011). 
 68. Id. 
 69. U.S. DEP’T HEALTH & HUMAN SERVS. ET AL., GUIDANCE FOR INDUSTRY: USING A 
CENTRALIZED IRB REVIEW PROCESS IN MULTICENTER CLINICAL TRIALS 4–5 (2006) [hereinafter 
GUIDANCE FOR INDUSTRY]. 
 70. Human Subjects Research Protections, 76 Fed. Reg. 44,512, 44,522 (proposed July 26, 
2011). Contra Protection of Human Subjects, 45 C.F.R. § 46.107(a) (2011) (stating the point of 
local IRBs is to gain the perspective of the community and for researchers to demonstrate the 
input of local comments on the requirements for a waiver of consent). 
 71. Kathleen Dziak et al., Variations Among Institutional Review Board Reviews in a 
Multisite Health Services Research Study, 40 HEALTH SERVS. RES. 279, 287 (2005). 
 72. Human Subjects Research Protection, 76 Fed. Reg. 44,512, 44,522 (proposed July 26, 
2011); Dziak et al, supra note 71, at 282–83 (examining a study evaluating patient perceptions of 
care at fifteen primary sites). See also Jansen, supra note 53, at 7. 
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Research integrity deals with verifiable methods in research and the adherence 
to rules, regulations, and guidelines in research.73 In addition to producing 
different outcomes, local IRBs sometimes made minor, site-specific 
modifications during local review of multi-site studies.74 These site-specific 
modifications can potentially undermine the scientific validity of a study 
because they introduce an uncontrolled variance.75 Another concern is the 
approval time discrepancy from institution to institution.76 The variability in 
the IRB approval process is cited as an “enormous challenge” to human-
subjects’ research.77 
Along with the concerns regarding multiple IRB reviews of a single 
protocol, HHS supported the central IRB mandate by suggesting that local 
review is not necessary and does not add protection for subjects.78 HHS cited 
to a report that found that there is no data to show that local perspectives are 
taken into consideration during local IRB review.79 Additionally, critics of the 
current system support the notion that a mandatory central IRB review would 
create a stronger local IRB system,80 since multiple reviews divert IRB 
resources from other studies.81 Along with retaining valuable resources, critics 
suggest that independent IRBs are less vulnerable to institutional pressures.82 
However, these challenges pit the interests of scientific research against the 
interests of human-subjects’ welfare. Although there is no evidence that 
additional local review helps protect subjects, clearly additional local review 
does not place subjects at a greater of risk of being injured in research studies. 
Additionally, these critics fail to address the serious implication that 
 
 73. Research Integrity, U.S. DEP’T HEALTH & HUMAN SERVS., http://grants.nih.gov/grants/ 
research_integrity/index.htm (last visited Apr. 19, 2013). 
 74. Jansen, supra note 53, at 7. 
 75. Id. at 8. 
 76. Dziak et al., supra note 71, at 283. The time it took for the fifteen IRBs to review the 
study ranged from five to 172 days. Id. HHS also cited to a report that indicated that the review 
time variability concerned study sponsors. Human Subjects Research Protection, 76 Fed. Reg. 
44,512, 44,522 (proposed July 26, 2011); NAT’L INST. OF HEALTH ET AL., NATIONAL 
CONFERENCE ON ALTERNATIVE IRB MODELS: OPTIMIZING HUMAN SUBJECT PROTECTION 6 
(2006), available at https://www.aamc.org/download/75240/data/irbconf06rpt.pdf [hereinafter 
NATIONAL CONFERENCE]. 
 77. Dziak et al., supra note 71, at 287. 
 78. Human Subjects Research Protection, 76 Fed. Reg. 44,512, 44,522 (proposed July 26, 
2011). 
 79. Ezekiel J. Emanuel et al., Oversight of Human Participants Research: Identifying 
Problems to Evaluate Reform Proposals, 141 ANN. INTERNAL MED. 282, 283 (2004). 
 80. Id. at 289. Reducing the burden on local IRBs would allow them to “focus on research 
requiring a local perspective.” Id. at 287. 
 81. Burman & Daum, supra note 54, at 330–31 (finding that a multi-site study required a 
median of thirty staff hours). 
 82. NATIONAL CONFERENCE, supra note 76, at 5. 
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independent IRBs are more vulnerable to sponsor pressure, since the sponsor is 
the IRB’s customer.83 While HHS’s rationale suggests that the regulations 
protect important research integrity issues, the proposed regulations were not 
based on any factual studies showing that a central IRB would improve 
research-subjects’ safety.84 
C. Recent Issues with IRBs: Why the Public Should Care About Research 
Subject Protection Regulations 
IRBs exist in order to protect research-subjects’ safety.85 Improving 
subject safety should be the top priority for new HHS regulations, especially 
given the track record of research-subjects’ protection. 
1. Research Subject Injuries: Effective IRB Regulations are Essential to 
Protecting Research Volunteers 
Research abuses still occur in the United States despite HHS regulations 
and IRB review of studies.86 Risks exist for any clinical trial participant, but 
recent cases of participant injury or death place into question whether financial 
conflicts of interest put subjects in a greater position of risk.87 While the more 
publicized research deaths may have occurred in studies governed by local 
IRBs,88 research subjects have been injured in studies governed by for-profit 
IRBs as well.89 
Perhaps the most publicized participant injury in recent years was the death 
of 18-year old Jesse Gelsinger at the University of Pennsylvania in 1999 
during a gene-therapy trial.90 The informed consent form Gelsinger signed 
failed to mention that several monkeys had died in a prior study91 and that four 
research subjects previously suffered severe liver damage.92 Unfortunately, 
Gelsinger’s death has not been an isolated incident where oversight has failed 
 
 83. See infra text accompanying notes 221–32. 
 84. Human Subjects Research Protection, 76 Fed. Reg. 44,512, 44,521–22 (proposed July 
26, 2011). 
 85. Institutional Review Boards, 74 Fed. Reg. 9,578 (proposed March 5, 2009) (to be 
codified at 45 C.F.R. pt. 46). 
 86. See infra text accompanying notes 91–105. 
 87. See infra text accompanying notes 98–105. 
 88. Commentators have pointed out that the highly publicized cases of human subjects 
injuries have been in single-site studies. Burman & Daum, supra note 54, at 332. 
 89. Ezekiel J. Emanuel et al., Should Society Allow Research Ethics Boards to Be Run as 
For-Profit Enterprises?, 3 PLOS MED. 941, 943 (2006). 
 90. Robin Fretwell Wilson, Estate of Gelsinger v. Trustees of University of Pennsylvania: 
Money, Prestige, and Conflicts of Interest in Human Subjects Research, in HEALTH LAW AND 
BIOETHICS 229, 229 (Sandra H. Johnson et. al. eds., 2009). 
 91. Id. 
 92. Sharona Hoffman, Continued Concern: Human Subject Protection, the Institutional 
Review Board, and Continuing Review, 68 TENN. L. REV. 725, 725 (2001). 
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to protect research subjects. Not long after Gelsinger’s death, Ellen Roche, a 
healthy volunteer, died in an asthma study conducted by Johns Hopkins 
University.93 Following Roche’s death, the FDA concluded that the study’s 
IRB review was “inadequate” 94 and suspended all federally-funded research at 
John Hopkins.95 These are just two cases that demonstrate how things can go 
wrong at prominent research institutions under local IRB review when the IRB 
and the researchers lose sight of their priority to protect research subjects.96 
Although less publicized, independent IRBs and multi-site studies have 
had recent issues with injured subjects as well. In 2002, Gary Polsgrove died 
twenty-two days after enrolling in a study at the Fabre Research Clinic in 
Houston.97 A Fabre Clinic employee, an employee represented to the FDA as a 
licensed physician’s assistant, with no actual medical training, was responsible 
for Polsgrove’s care during the study.98 The IRB reviewing the study—the 
Human Investigation Committee—was run by Fabre, the same man who ran 
the research clinic.99 This “IRB held its meetings in restaurants around 
Houston.”100 Even though the FDA issued a warning to the IRB in 1992 
highlighting its conflict of interest, the IRB continued to review studies at the 
Fabre Clinic, including the study in which Polsgrove was enrolled.101 In 2004, 
 
 93. Hazel Glenn Beh, The Role of Institutional Review Boards in Protecting Human 
Subjects: Are We Really Ready to Fix a Broken System?, 26 LAW & PSYCHOL. REV. 1, 32 (2002). 
Ellen Roche died on June 3, 2001. Id. 
 94. Jonathan Bor & Tom Pelton, U.S. Halts Hopkins Research, THE BALTIMORE SUN (July 
20, 2001), http://www.baltimoresun.com/bal-te.hopkins20jul20,0,5166731.story. 
 95. Beh, supra note 93, at 32. 
 96. Daniel L. Icenogle & Whyte H. Dudek, IRBs, Conflicts and Liability: Will We See IRBs 
in Court? Or is it When?, 1 CLINICAL MED. & RES. 63, 64 (2002). Other stories include Kathryn 
Hamilton’s death in a breast cancer study at the renowned Fred Hutchinson Cancer Center and 
nine-month-old Gage Steven’s death in a heartburn study at Pittsburgh Children’s Hospital. Duff 
Wilson & David Heath, With a Year or Two to Live, Woman Joined Test in Which She was 
Misled-and Died, SEATTLE TIMES (Mar. 13, 2001), http://community.seattletimes.nwsource.com/ 
archive/?date=20010313&slug=hutch13; Dawn MacKeen, Kids as Guinea Pigs, SALON (May 31, 
2000), http://www.salon.com/2000/05/31/drug_trials/. The shocking part about Hamilton’s story 
is that only six days after Hamilton passed, her doctors published a study concluding that the 
drugs did not work. Wilson & Heath, supra note 96. 
 97. DAVID EVANS ET AL., BLOOMBERG MARKETS, BIG PHARMA’S SHAMEFUL SECRET 4 
(2005), available at http://dcscience.net/pharma-bloomberg.pdf. 
 98. Id. Astoundingly, a similar situation was uncovered in 2010 when Doctor Kamrava at 
Napoli LLC conducted a clinical study that was approved by the local IRB at West Coast IVF 
Clinic, of which Doctor Kamrava and an embryologist were the IRB’s only members. Letter from 
Steven D. Silverman, Dir., Ctr. for Devices and Radiological Health, to Michael M. Kamrava, 
Chairman, Int’l Review Bd. (Jan. 21, 2011) (on file with the U.S. Dep’t of Health & Human 
Servs.), available at http://www.fda.gov/ICECI/EnforcementActions/WarningLetters/2011/ucm2 
40960.htm. 
 99. EVANS ET AL., supra note 97, at 4. 
 100. Id. 
 101. Id. 
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Western IRB, the nation’s largest for-profit IRB,102 settled a lawsuit with a 
research subject for an undisclosed amount after the subject, whose psoriatic 
arthritis was under control before the study, became so ill during the study that 
he could barely walk or stand.103 Other injuries in multi-site studies include the 
death of a 19-year old University of Rochester student in a Massachusetts 
Institute of Technology study.104 In addition to these notorious injuries and 
deaths, research-subjects’ injuries have prompted lawsuits against IRBs.105 
2. IRB Liability: Can IRBs Be Held Liable for Failing to Protect 
Research Subjects? 
Neither the OHRP nor the FDA can require an institution or an IRB to pay 
damages to an injured research subject.106 Although injured research subjects 
have been suing institutions and researchers for a long time, litigation against 
IRBs has increased in the past decade.107 Although injured participants have 
not won a court verdict against an IRB, there are cases where IRBs, including 
for-profit IRBs, have settled with plaintiffs outside of the courtroom.108 
However, this lack of success in the courtroom has not deterred plaintiffs from 
adding IRBs and individual IRB members as defendants to lawsuits. 109 
Injured research subjects first opened the door to suing IRB members in 
Robertson v. McGee.110 Robertson arose out of a study at the University of 
Oklahoma Health Science Center.111 The plaintiffs alleged that the “IRB 
members failed to examine the design of the protocol, review the operation of 
the trial, review proposed amendments to the informed consent forms, review 
 
 102. Caroline McNeil, Debate Over Institutional Review Boards Continues as Alternative 
Options Emerge, 99 J. NAT’L CANCER INST. 502, 502 (2007). 
 103. EVANS ET AL., supra note 97, at 6. 
 104. Dan McGuire, Rochester Death Halts MIT Funded Study, THE TECH, April 9, 1996, 
available at http://tech.mit.edu/V116/PDF/N17.pdf. 
 105. Marjorie Ellen Zettler, Trials and Tribulations of the IRB Member, 80 U. TORONTO 
MED. J. 200, 200–01 (2003). 
 106. Sharona Hoffman & Jessica Wilen Berg, The Suitability of IRB Liability, 67 U. PITT. L. 
REV. 365, 416 (2005). 
 107. See id. at 382–84; See Zettler, supra note 105, at 201. 
 108. EVANS ET AL., supra note 97, at 6 (disclosing that Western IRB settled with Bill Hamlet 
for an undisclosed amount); Hoffman & Berg, supra note 106, at 382; Beh, supra note 93, at 29, 
31–32 (disclosing the University of Pennsylvania settled with the Gelsinger family after Jesse 
Gelsinger’s death). 
 109. See generally, infra text accompanying notes 114–17; see also T.C. ex rel. v. A.I. 
DuPont Hosp. for Children, 368 F. App’x 285, 286–87 (3d Cir. 2010); M.G. ex rel. v. A.I. 
DuPont Hosp. for Children, 393 F. App’x 884, 885–86 (3d Cir. 2010). 
 110. Hoffman & Berg, supra note 106, at 383. 
 111. Robertson v. McGee, No. 01-CV-60-C, 2002, U.S. Dist. LEXIS 4072, at *5 (D. Okla. 
Jan. 28, 2002). 
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amendments to the protocol, and ensure proper reporting.”112 However, the 
Robertson court did not issue a ruling on the merits because the court 
concluded that it lacked subject-matter jurisdiction.113 Similarly, in Townsend 
v. University Hospital-University of Colorado, a research subject’s family 
members sued the individual members of the University of Colorado IRB after 
the subject died in the hospital’s care.114 In this case, the IRB member liability 
issue was not decided because the court lacked personal jurisdiction.115 In 
addition to these decided IRB cases, there are also cases currently pending 
against IRBs. An injured subject filed a complaint in April 2011 against the 
individual members of an IRB for failing to use due care in approving a gene 
therapy protocol.116 Another recently filed lawsuit against Duke University 
took a different approach by suing Duke directly for negligence per se for its 
IRB’s failure to “renew its review of the research as other renowned 
researchers called the Duke University and/or DUHS Clinical Trials into 
question.”117 
Multiple theories have been proposed to hold IRBs liable for research- 
subject injuries. IRB liability does not fall within typical liability grounds 
because the IRB does not contract directly with research subjects or make 
direct representations to them.118 Furthermore, the Common Rule does not 
create a private right of action against an IRB.119 However, IRB members may 
be found negligent for not taking precautions to ensure that protocols complied 
with applicable regulations if the plaintiff can demonstrate causation and 
damages.120 For example, in Kus v. Sherman Hospital, an Illinois Appellate 
Court held that the IRB could be liable for negligence if it violated a statutory 
duty imposed by federal regulations.121 
Others have suggested filing claims against IRBs under the False Claims 
Act (FCA), although no decisions have been reached on the merits against an 
 
 112. Icenogle & Dudek, supra note 96, at 65. 
 113. Robertson v. McGee, No. 01-CV-60-C, 2002, U.S. Dist. LEXIS 4072, at *13 (D. Okla. 
Jan. 28, 2002). 
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 115. Id. 
 116. Complaint at 32–33, Zeman v. Williams et al., 2011 WL 552700 (D. Mass. 2011) (No. 
1:11-CV-10204). 
 117. Complaint & Demand for Jury Trial at 213, Aiken v. Duke Univ., et al., 2011 WL 
4956867 (N.C. Super. 2011) (No. 11 CVS 4721). 
 118. NATIONAL CONFERENCE, supra note 76, at 15. 
 119. Id. at 16. 
 120. Beasley, supra note 114, at 59. 
 121. David B. Resnik, Liability for Institutional Review Boards, 25 J. OF LEGAL MED. 131, 
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Review Boards, 21 C.F.R. § 56.107 (2012). 
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IRB under the FCA.122 In order to file under the FCA alleging violations of the 
Common Rule, a plaintiff must meet three conditions: “(1) the government, 
specifically OHRP, is not aware of the violations; (2) the violations are 
substantive, material to the government’s decision to fund, and not merely 
technical; and (3) the IRB knew that the research violated the federal 
regulations or was reckless in applying them.”123 Because the plaintiff need not 
show personal injury, the FCA may be an attractive alternative when proof of 
causation is challenging.124 One of the major benefits of the FCA is that 
society can proactively fix “problem” IRBs instead of having to wait until a 
research subject is seriously injured or killed in order to file a suit.125 However, 
a plaintiff may have difficulty in this type of suit demonstrating that the IRB 
presented a false claim or caused a false claim to be presented.126 
Another avenue for recovery would be to consider injured research 
subjects as third-party beneficiaries to the contract between the federal agency 
and the research institution.127 The contract should be looked at as providing 
the terms under which research protocols must be approved, instead of as a 
contract to provide potential therapeutic benefits. Therefore, the research 
subjects would be beneficiaries of this contract.128 Additionally, fiduciary 
theory may be an attractive avenue for recovery if the plaintiffs find it 
challenging to prove the elements of negligence.129 In this scenario, plaintiffs 
would have to prove that IRB members are fiduciaries and to identify the IRB 
members’ defined role.130 
Not only have IRBs been able to escape liability for research decisions, 
plaintiffs can also have trouble requesting IRB documents.131 The laws in some 
 
 122. Daniel J. Powell, Using the False Claims Act as a Basis for Institutional Review Board 
Liability, 69 U. CHI. L. REV. 1399, 1400 (2002). 
 123. Id. at 1416. 
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 125. Id. at 1419. 
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states, like Illinois, place the priority in protecting IRBs and researchers over 
protecting research subjects.132 This misalignment of priorities misses the point 
of IRBs—IRBs exist to protect research subjects. 
The fact that serious issues have occurred both with local IRBs and for-
profit IRBs only highlights the issue that HHS’s system is not working to 
protect research subjects. While inadequate ethics review is unacceptable, a 
company making money off of reviewing its own research is morally 
repugnant. Regulations should not push more studies toward for-profit 
companies without safeguards in place to prevent this type of occurrence. 
II.  PROPOSED REGULATIONS DO NOT PLACE RESEARCH-SUBJECTS’ 
PROTECTION AS TOP PRIORITY 
A. Mandating Central IRB Review Effectively Means Overworked Local 
IRBs Will Defer to Independent IRBs for Multi-Site Studies 
The implications of the proposed regulations on research-subjects’ safety 
are unknown, since no studies exist to show that central IRBs are better for 
subject protection.133 However, the few studies on central IRBs that do exist 
suggest that it would not be feasible for local IRBs to become the central IRB 
for multi-site studies. With that being said, there is limited data from which to 
draw these predictions because IRB databases are nonexistent.134 
IRB operating costs vary substantially from IRB to IRB.135 Although total 
IRB costs are debatable, there is consensus that local IRBs are overworked.136 
Overworked local IRBs are not likely to want, nor are they likely to be able to, 
take on the additional responsibility of overseeing multi-site reviews. Due to 
 
“process review” rather than “peer review.” Dieffenbach, 715 F. Supp. 2d at 596. IRBs protect 
human subjects by collecting and disseminating information about the studies, even to the public. 
Id. The court in Illinois Masonic Medical Center noted that the Illinois statute was broader than 
the Minnesota statute in Konrady. 696 N.E.2d at 710. 
 132. Illinois Masonic Medical Center, 696 N.E.2d at 711 (concluding that the IRB did not 
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 133. Human Subjects Research Protection, 76 Fed. Reg. 44,512, 44,522 (proposed July 26, 
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sponsors for review. Emanuel et al., supra note 79, at 283. 
 136. Beh, supra note 93, at 35. 
SAINT LOUIS UNIVERSITY SCHOOL OF LAW 
2013] IS THE CUSTOMER ALWAYS RIGHT? 427 
limited IRB resources,137 taking on multi-site studies might steal valuable 
resources away from institutional research studies. A single multi-site study 
may capture a large portion of an IRB’s budget for multiple years. 
Additionally, many institutions do not compensate their IRB members for 
individual efforts,138 meaning any additional IRB work detracts from 
members’ compensated duties. IRBs that are already struggling with providing 
adequate continuing review139 are unlikely to take on studies with significantly 
more challenging continuing review. 
If a local IRB were to be the central IRB for a multi-site study, the time 
costs of review and continuing review would be a concern. Although initial 
review would be similar to a regular IRB review, the time cost would be 
greater since the IRB would have to consider the local context at each site.140 
Under 21 C.F.R. § 56.107(a), IRB members have to “ascertain the 
acceptability of the proposed research in terms of institutional commitments 
and regulations, applicable law, and standards or professional conduct and 
practice.”141 The local IRB would have to become aware of local community 
concerns at every site in the multi-site study and document these concerns in 
meeting minutes.142 Relevant community concerns include local attitudes and 
local research laws: laws on consent, laws on confidentiality relating to 
substance abuse, laws on mental healthcare, and laws on HIV/AIDs status.143 
Mechanisms for ensuring adequate local review could include forms, to be 
filled out by individuals familiar with the local community, that request 
relevant local information; consultant interviews; or requests for written input 
from local IRB members at each site.144 Whichever mechanism is chosen, local 
community concerns will provide a significant challenge for an unprepared 
local IRB. 
Local IRBs, which are familiar with reviewing studies where they know 
the researchers,145 will have to spend time and money on training to learn how 
to work with unfamiliar institutions, IRB members, and communities. The 
 
 137. IRBs have “inadequate resources, unmanageable workloads, and, in some cases, 
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(2005) (finding 43 percent of institutions do not provide monetary compensation to IRB members 
in a 2002 survey). 
 139. Hoffman, supra note 92, at 748–49. 
 140. GUIDANCE FOR INDUSTRY, supra note 69, at 2. 
 141. Institutional Review Boards, 21 C.F.R. § 56.107(a) (2001). 
 142. Wagner et al., supra note 134, at 817; GUIDANCE FOR INDUSTRY, supra note 69, at 5 
(citing 21 C.F.R. § 56.115(a)). 
 143. Lis & Murray, supra note 66, at 98–102. 
 144. GUIDANCE FOR INDUSTRY, supra note 69, at 5. 
 145. Wagner et al., supra note 134, at 817. 
SAINT LOUIS UNIVERSITY SCHOOL OF LAW 
428 SAINT LOUIS UNIVERSITY PUBLIC LAW REVIEW [Vol. XXXII:411 
institutions may have conflicting policies and procedures, which would have to 
be considered in order to preserve the ethical beliefs of each institution.146 For 
example, Catholic institutions will have different rules than non-
denominational institutions.147 In addition, there would be an added time cost 
to familiarize IRB members with other states’ applicable laws.148 State laws 
play an important role in research conduct,149 as federal regulations do not 
override state laws, which provide additional protection for research 
subjects.150 Since many IRBs do not have budgets, re-training staff members to 
deal with off-site studies may be cost-prohibitive, time-prohibitive, and 
undesirable.151 
Continuing review will also be a major concern for local IRBs, and the 
importance of continuing review cannot be overlooked.152 Separating the 
reviewers from the research study site makes the IRB’s job in monitoring 
research even more difficult.153 Since staff and board time costs are the 
majority of IRB costs, the amount of staff and board hours to cover continuing 
review of far-away institutions would significantly increase IRB costs.154 Local 
IRBs may not have the resources to adequately review different sites.155 Not 
only would travel time increase, but technology costs—faxes, phones, web 
pages, databases—would likely increase as well for an IRB to sufficiently 
review off-site locations.156 Since IRBs are already struggling with providing 
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adequate continuing review,157 the daunting task of following-up at every 
research site may be enough in itself to deter local IRBs from becoming central 
IRBs for multi-site studies. Consequently, local IRBs may not desire to 
become a central IRB for multi-site studies. 
In addition to the burdens on the local IRB, there is no evidence that 
sponsors would choose to work with local IRBs when turnaround time at 
independent IRBs is significantly faster.158 In a recent study, initial review at 
the National Cancer Institute (NCI) Central IRB averaged 7.9 hours, compared 
to the mean time of 14 hours at local IRB sites.159 In addition to IRB staff time, 
there was also a difference in the number of days it took to get the study 
passed.160 At the central IRB site, the entire approval process took, on average, 
28.3 days, while the approval process averaged 62.3 days at the local sites.161 
Since sponsors value faster and more predictable reviews, they are willing to 
pay to use independent IRBs.162 Because there are few nonprofit, independent 
IRBs, the majority of the independent IRBs used by sponsors are for-profit 
companies.163 While these for-profit IRBs may be more efficient for sponsors, 
relying solely on independent IRBs for multi-site studies raises concerns 
regarding the welfare of research subjects. 
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Inspector General statement criticizing IRBs for failing to provide adequate continuing review of 
studies. Wagner et al., supra note 134, at 822. 
 158. One study found the average decision time for independent IRBs to be eleven days 
compared with thirty-seven days for academic IRBs. Lis & Murray, supra note 66, at 87. See also 
Todd H. Wagner et al., Costs and Benefits of the National Cancer Institute Central Institutional 
Review Board, 28 J. OF CLINICAL ONCOLOGY 662, 664 (2010), available at http://www.ncbi.nlm. 
nih.gov/pmc/articles/ PMC2816001/pdf/zlj662.pdf. 
 159. Wagner et al., supra note 158, at 664. 
 160. Id. 
 161. Id. 
 162. Id. at 665. 
 163. Compare Macklin, supra note 23, at 19 (stating that there are some not-for-profit 
independent IRBs, but that information on them is scarce), with Commercial Institutional Review 
Boards, supra note 23 (listing forty-six active commercial IRBs). 
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B. Independent IRBs are not in the Research-Subjects’ Best Interests 
1. Broken Independent IRBs 
Although IRB subject safety issues are not isolated to independent IRBs,164 
local IRB issues do not make for-profit IRB problems go away.165 The two 
recent sting operations involving Coast IRB and Essex IRB illustrate major 
concerns with mandating the use of central IRBs without any changes in 
research-subjects’ protection or without requiring any additional oversight of 
for-profit IRBs. As shocking as the Coast IRB incident was, the Essex IRB 
incident was unnerving. HHS has not done anything in the past two years to 
remedy the “rubber-stamping” highlighted in the Coast IRB sting operation. 
In late 2008, the Government Accountability Office (GAO) created a fake 
protocol, based on a study for a product that the FDA had removed from the 
market after patient deaths, and submitted the protocol to three IRBs to 
determine whether IRBs were “rubberstamping” research studies.166 Coast IRB 
approved this protocol unanimously, 7-0.167 The other two IRBs, who rejected 
the study protocol, commented that the study was “the most complicated thing 
that I have ever seen” and was “a terrible risk for the patient.”168 They both 
questioned patient safety in the protocol.169 Whereas, Coast IRB’s primary 
reviewing doctor told the board members that the protocol “looks fine” and 
that it was “probably very safe.”170 Furthermore, Coast IRB was only given 
information on 2.5 percent of the product, and the board never asked what 
made up the other 97.5 percent of the product that was to be placed in the 
subject’s body.171 Coast IRB discovered the fraud only after being contacted 
by congressional investigators five months after approval.172 Therefore, 
experimentation with this deadly product could have been occurring on 
research subjects for five months.173 
 
 164. IRB Seals Fate by Approving Fake Protocol in Federal Sting, IRB ADVISOR, July 1, 
2009 (statement of Marjorie Speers, Executive Director, AAHRPP). 
 165. Emanuel et al., supra note 89, at 944. 
 166. Hearing on IRBs, supra note 1, at 4 (statement of Rep. Bart Stupak, Chairman, Comm. 
on Energy and Commerce). 
 167. Id. at 5. 
 168. Id. One of the IRBs unanimously rejected the protocol. Id. 
 169. Id. 
 170. Id. 
 171. Hearing on IRBs, supra note 1, at 42. 
 172. Id. at 5 (statement of Rep. Bart Stupak, Chairman, Comm. on Energy and Commerce). 
 173. Id. at 27 (statement of Gregory Kutz, Managing Director, Government Accountability 
Office) (declaring that since federal money was not involved, Coast IRB approval was the only 
step necessary before experimentation). 
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Coast IRB had reviewed thousands of clinical trials before the sting 
operation,174 and it had overseen 300 studies in the month prior to the 
investigation.175 Its lax “review” of this product raises questions regarding the 
quality of review it gave all of the other studies it had overseen in the past. In 
fact, Coast IRB approved all 356 protocols it reviewed in the previous five 
years, with only a single dissenting vote.176 That means that only one out of 
2,492 votes over five years was a vote to disapprove a study.177 In the 
meantime, Coast IRB’s revenue more than doubled from 2004 to 2008 to $9.3 
million.178 
Moreover, Coast IRB had other conflicts with the FDA prior to this sting 
operation. On March 11, 2008, Coast IRB received a warning letter from the 
FDA regarding regulatory violations.179 Coast IRB allowed an inexperienced 
IRB member, an employee with only a high school education,180 to conduct an 
expedited review of a study, which did not qualify for expedited review.181 
Coast IRB directed the member to conduct the review despite the full board’s 
disapproval of the study’s recruitment advertisement.182 The FDA also cited 
Coast IRB for not following its own standard operating procedures.183 As a 
result, the FDA suspended Coast IRB’s ability to use expedited review 
procedures.184 Just a year later, the FDA issued its death-inducing warning 
letter to Coast IRB relating to the sting operation.185 The FDA cited Coast IRB 
for multiple failures in not obtaining sufficient information to identify any 
reasonably foreseeable risks to subjects.186 As a result, on April 14, 2009, 
 
 174. Id. at 15. 
 175. Barry Meier, Medical Review Firm, After Federal Sting, Goes out of Business, N.Y. 
TIMES (Apr. 23, 2009), http://www.nytimes.com/2009/04/23/business/23coast.html. 
 176. Hearing on IRBs, supra note 1, at 46 (statement of Rep. Edward J. Markey). 
 177. Id. In contrast, one of the other IRBs contacted by the GAO in this sting operation had 
seven votes of disapproval in this study alone. Id. (statement of Rep. Bart Stupak, Chairman, 
Comm. on Energy and Commerce). 
 178. Meier, supra note 175. 
 179. Letter from Leslie K. Ball, Dir., Food & Drug Admin., to Darren McDaniel, Chief Exec. 
Officer, Coast Institutional Review Board (Mar. 11, 2008) (on file with U.S. Dep’t of Health & 
Human Servs.), available at http://www.fda.gov/ICECI/EnforcementActions/WarningLetters/ 
2008/ucm1048374.htm [hereinafter Coast Letter 2008]. 
 180. Hearing on IRBs, supra note 1, at 33 (statement of Rep. Donna M. Christensen). 
 181. Coast Letter 2008, supra note 179. 
 182. Id. 
 183. Id. 
 184. Id. 
 185. Letter from Deborah M. Autor, Dir., Ctr. for Drug Evaluation & Res., to Daniel Dueber, 
Chief Exec. Officer, Coast Institutional Review Board (Apr. 14, 2009) (on file with U.S. Dep’t of 
Health & Human Servs.), available at http://www.fda.gov/ICECI/EnforcementActions/Warning 
Letters/2009/ucm136673.htm. 
 186. Id. Failure to determine risks to subjects were minimized under 21 C.F.R. 56.111(a); 
failure to determine that risks to subjects were reasonable in relation to anticipated benefits under 
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Coast IRB voluntarily agreed to review no new studies as well as not to add 
subjects to ongoing studies.187 Only a few days later, Coast IRB closed shop 
for good.188 
In response to the sting operation, Coast IRB’s Chief Executive Officer 
(CEO) lashed out at the government, telling congressional investigators that 
they “wasted five weeks of my valuable time” and that it was 
“unconscionable” for his government to do this to him.189 Additionally, Coast 
IRB did not fire any employees after the incident, not even the IRB chairman 
who admitted to not reading the protocol.190 The fact that Coast IRB’s CEO 
was more concerned about his company’s reputation than he was about 
potential safety breaches in his company makes one wonder where Coast IRB 
placed its priorities.191 
Fast-forward two years. The same day that HHS released these proposed 
regulations, the FDA issued a warning letter to Essex IRB for approving a fake 
study192 based on a drug that was withdrawn from the market in 2004 after an 
increased risk of heart attacks and strokes.193 Essex IRB approved a trial from 
the same made-up sponsor and clinical investigator that was used in the Coast 
IRB sting.194 In addition, Essex IRB took a known adverse event out of the 
informed consent form without documenting its rationale for the removal.195 
Essex IRB could not produce meeting minutes that documented actions taken 
by the IRB, and it failed to follow its standard operating procedure.196 As a 
 
21 C.F.R. 56.111(a)(2); failure to make a risk determination; and failure to ensure basic elements 
of informed consent in consent form. Id. 
 187. Id. 
 188. Coast IRB Folds After FDA Warning, GAO Sting, BIOWORLD TODAY 1, 8 (Apr. 24, 
2009). 
 189. Hearing on IRBs, supra note 1, at 76–77 (statement of Daniel Dueber, CEO, Coast IRB, 
LLC). 
 190. Id. at 81. 
 191. Id. at 78. 
 192. Who Watches the Watchmen? 476 NATURE 125 (Aug. 11, 2011). This sting operation 
was run by journalists. Id. Essex IRB was considered a major for-profit IRB in 2006. Emanuel et 
al., supra note 89, at 943. 
 193. U.S. DEP’T OF HEALTH & HUMAN SERVS., MAR. 14–21 INSPECTION OF ESSEX 
INSTITUTIONAL REVIEW BOARD, INC. (Mar. 21, 2011), available at http://www.circare.org/fda 
wls/essexirb_fdafoia_2011-6068.pdf. Essex IRB failed to warn for the potential cardiovascular 
risk in the informed consent form. Id. 
 194. Id. 
 195. Id. 
 196. Id. Essex only discovered the fictitious study after the FDA posted an alert regarding a 
phony research application. Mari Serebrov, SEC Files Fraud Charges Against Biotech, 
Executives, 22 BIOWORLD TODAY 1, 5 (Aug. 4, 2011). 
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result, the FDA required Essex IRB to make changes and to submit audits of 
ongoing pediatric studies.197 
Essex IRB, like Coast IRB, had run into trouble with the FDA in the past. 
In 1998, Essex IRB failed to consider local conditions and standards in initial 
review and continuing review of studies.198 In response to these citations, the 
FDA stopped Essex IRB from approving new studies until the office had 
assurance that corrections were made.199 In 2000, Essex IRB failed to conduct 
adequate continuing review and failed to fulfill requirements for expedited 
review.200 Again, Essex IRB failed to prepare adequate IRB documents.201 The 
FDA concluded that Essex IRB’s procedures were inadequate to protect the 
rights of research subjects.202 
Essex IRB’s response to the latest citations raises questions about its 
business’s priorities as well. Essex IRB responded in a letter to the FDA in a 
similar manner that Coast IRB’s CEO responded in the congressional 
hearings.203 Essex IRB expressed that its IRB was designed to review clinical 
research and not to detect fabricated submissions.204 
Although an incident as flagrant as making up a company and a drug has 
not occurred, research scientists have been convicted or accused of fraudulent 
activity, making it important for IRBs to be able to isolate these issues. A 
lawsuit filed in September 2011 accused a Duke University researcher of 
falsifying medical research.205 In addition, in 2011, two researchers at the Lee 
 
 197. Letter from Leslie K. Ball, Dir., Food & Drug Admin., to Nancy Waggoner, Chief Exec. 
Officer, Essex Institutional Review Board, Inc. (July 26, 2011) (on file with U.S. Dep’t of Health 
& Human Servs.), available at http://www.fda.gov/ICECI/EnforcementActions/WarningLetters/ 
2011/ucm266114.htm. 
 198. Letter from David A. Lepay, Dir., Ctr. for Drug Evaluation & Res., to William C. 
Waggoner, President & Chairman, Essex Institutional Review Board, Inc. (Aug. 27, 1998) (on 
file with U.S. Dep’t of Health & Human Servs.), available at http://www.fda.gov/downloads/ICE 
CI/EnforcementActions/WarningLetters/1998/UCM066739.pdf. 
 199. Id. 
 200. Letter from Steven A. Masiello, Dir., Ctr. for Biologics Evaluation & Res., to Glenn P. 
Lambert, Chairman, Essex Institutional Review Board, Inc. (Mar. 01, 2000) (on file with U.S. 
Dep’t of Health & Human Servs.), available at http://www.fda.gov/downloads/ICECI/Enforce 
mentActions/WarningLetters/2000/UCM068175.pdf. 
 201. Id. Essex IRB also failed to record the attendance and voting of IRB members. Id. 
 202. Id. 
 203. Letter from Glenn P. Lambert, Chairman, Essex Institutional Review Board, Inc., to 
Douglas I. Ellsworth, District Dir., Food & Drug Admin. (Apr. 11, 2011) (on file with author), 
available at http://www.circare.org/fdawls/essexirb_fdafoia_2011-6068.pdf. 
 204. Id. 
 205. Duke University was sued for negligence per se for the IRB’s failure. Complaint at 1, 
Aiken v. Duke Univ., No. 11 CVS 4721 (N.C. Super. Ct. Sept. 7, 2011) (alleging that plaintiffs 
were exposed to improper and unnecessary chemotherapy due to falsified medical research). 
Researcher at the University of Texas MD Anderson Cancer Center issued warnings that the 
research was faulty to the researchers and to Duke University from 2006-07. Id. at 10. Nature 
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Research Institute in Lenexa, Kansas were charged with falsifying study data 
in a clinical drug trial.206 Along with the 2011 incidents, 2010 saw multiple 
papers retracted from journals after scientific misconduct or data 
falsification.207 Doctors have also strayed in research, which has impacted 
patient care and the medical market.208 For example, a Massachusetts 
anesthesiologist was convicted of health care fraud after falsifying clinical 
research about pain management producing six false articles over six years.209 
Unfortunately, issues of fraud need to be considered at every step for research-
subjects’ protection. Since IRBs’ primary responsibility is to ensure protection 
of subjects, IRB review processes must be robust enough to detect fraudulent 
activity. 
2. Safety Issues for Research Subjects under Central IRB Mandate 
There is not any published evidence that demonstrates how well a central 
IRB would work to protect research subjects in all multi-site studies.210 
Although there is some IRB efficiency data, IRB efficiency metrics do not 
consider IRB quality.211 The NCI is currently working on a pilot study where 
the local IRBs at twenty-five sites are responsible for reviewing local context 
and the central IRB does not consider local context.212 Why propose 
 
Medicine published in a November 2007 issue the MD Anderson researcher’s notice letter 
pointing out errors in the study. Id. at 14. A University of Michigan researcher highlighted the 
same issues. Id. at 17. 
 206. Indictment at 1, United States v. Sharp, No. 5:11-cr-40042-RDR (D. Kan. June 1, 2011). 
The researchers allegedly knowingly accepted two subjects that were not qualified for a study due 
to age and employment. Id. at 6. 
 207. On September 24, 2010, more papers, making a total of six papers, were retracted after 
scientists were accused of scientific misconduct; in December 2010, the International Anesthesia 
Research Society retracted a paper after finding falsified data. Praveen K. Neema, Medical 
Research: Is Everything Alright?, 27 J. ANAESTHESIOLOGY CLINICAL PHARMACOLOGY 155, 
159–61 (2011). 
 208. Sentencing Memorandum at 8, United States v. Reuben, No. 10-CR-30002-MAP (D. 
Mass. June 22, 2010); 
Brendan Borrell, A Medical Madoff: Anesthesiologist Faked Data in 21 Studies, SCI. AM. (Mar. 
10, 2009), http://www.scientificamerican.com/article.cfm?id=a-medical-madoff-anesthestesiolo 
gist-faked-data. Studies resulted in “the sale of billions of dollars of the potentially dangerous 
drugs . . . Celebrex and Vioxx.” Id. 
 209. Reuben, No. 10-CR-30002-MAP at 3–4. Reuben received a six-month sentence for the 
fraud. Neema, supra note 207, at 159. 
 210. The NCI Central IRB model does not scale well. Memorandum from National Heart, 
Lung, and Blood Institute Working Group, Facilitating NHLBI Clinical Trials Through 
Optimization of the IRB Process: Are Central IRBs the Solution (June 28–29, 2011) (on file with 
author). Without evidence demonstrating appropriate parallels between the NCI and other central 
IRBs, studies using the NCI Central IRB are not effective in showing central IRB efficacy. 
 211. Id. 
 212. Id. Pilot will be evaluated in late 2012. Id. 
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regulations to force multi-site studies to use a central IRB for local review 
before finding out the results of this study? The NCI needs to develop metrics 
to assess the quality of IRB review before removing additional eyes of 
protection.213 There is just not any information out there that shows how often 
issues arise related to local context.214 Additionally, current NCI data should 
not be used as a model for a mandatory central IRB because NCI parameters 
vary from the proposed central IRB regulations in vital aspects. For example, 
with the NCI, a majority of institutions still use their own local review for NCI 
studies,215 which would be discouraged under the proposed regulations. 
Moreover, the NCI central IRB is required to have the expertise to adequately 
assess the protocol.216 The proposed regulations have no such requirement for 
the central IRB in multi-site studies.217 A central IRB will not function to 
protect subjects if it does not have the expertise to adequately assess the 
protocol. Therefore, additional studies are necessary from sources that model 
the proposed regulations in order to accurately determine that a central IRB 
would adequately protect research subjects. 
Although there is limited information on the effectiveness of a mandatory 
central IRB, it is well known that independent IRBs inherently have conflicts 
of interests. The Institute of Medicine defines a conflict of interest as a 
circumstance that creates a risk that a primary interest—the promotion of and 
protection of research integrity and research-subjects’ welfare—will be 
“unduly influenced by a secondary interest,” such as financial interests, pursuit 
of professional advancement, and the desire to do favors for others.218 
Conflicts of interest place scientific integrity into question, and they jeopardize 
public trust in research.219 
Independent IRBs have a conflict of interest regardless of whether they are 
actually influenced by the secondary interest.220 For-profit IRBs have an 
 
 213. Id. 
 214. Nancy N. Dubler, National Heart, Lung, and Blood Institute Working Group, Central 
IRB Considerations: Issues of Ethics and Liability (June 28–29, 2011) (on file with author). 
 215. Emanuel Proposes U.S. Move to Regional IRB System, 12 GUIDE TO GOOD CLINICAL 
PRAC. NEWSL. 12 (2005). See also Winifred A. Meeker-O’Connell, Institutional Review Boards: 
Current Compliance Trends and Emerging Models, 9 J. OF HEALTH CARE COMPLIANCE 5, 8–9 
(2009) (stating that as of May 2005, only about a quarter of participating sites accepted the CIRB 
review). 
 216. IRB Models: Institutions Consider Central IRB Variations, 12 GUIDE TO GOOD 
CLINICAL PRAC. NEWSL. 18 (2004). Oncologists and other health care practitioners are on the 
NCI’s Central IRB Board. Meeker-O’Connell, supra note 215, at 8. 
 217. Human Subjects Research Protections, 76 Fed. Reg. 44,512 (proposed July 26, 2011) (to 
be codified at 21 C.F.R. pt. 50, 56). 
 218. INSTITUTE OF MEDICINE, CONFLICTS OF INTEREST IN MEDICAL RESEARCH, 
EDUCATION, AND PRACTICE 6 (2009). 
 219. Id. at 2. 
 220. See id. at 47. 
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incentive to approve clinical trials: if the IRB does not approve the trial, the 
applicants may use a different IRB for the succeeding study.221 Employees are 
well aware that rejecting protocols is not good for the company’s bottom 
line.222 This long-term relationship between independent IRBs and sponsors 
increases the risk that the sponsors influence independent IRB behavior.223 
Many question whether for-profit IRBs can “impartially assess industry-
sponsored research when their revenue comes from the very firms funding the 
studies.”224 Although funding for administrative review at an institution may 
seem similar to funding a for-profit IRB, the IRB members at the institution 
are not paid directly by the sponsors nor does the institution make a profit from 
the funding, in contrast to for-profit IRBs.225 Even though local IRBs may have 
ulterior motives, such as prestige, to approve trials, money is the “most 
powerful incentive to cut corners.”226 
In comparison, judges who have financial conflicts of interest are 
disqualified from review when there is “clear potential for personal loss” and 
when “the financial interest is not too remote.”227 Additionally, physician 
interaction with pharmaceutical companies is highly regulated.228 Scrutinizing 
financial conflicts of interests is appropriate for IRB review, especially when 
the research takes place within a commercial context.229 Uninfluenced IRB 
 
 221. Who Watches the Watchmen?, supra note 192. 
 222. Lemmens & Freedman, supra note 51, at 567. 
 223. See INSTITUTE OF MEDICINE, supra note 218, at 54. 
 224. Meeker-O’Connell, supra note 215, at 7. 
 225. See id. 
 226. Who Watches the Watchmen?, supra note 192. The cutting of corners could be 
subconscious, but there is data that money and bias go hand-in-hand in research. See generally 
Katherine Harmon, Industry-Sponsored Drug Trials More Likely to Report Positive Results, SCI. 
AM., http://blogs.scientificamerican.com/observations/2010/08/02/industry-sponsored-drug-trials-
more-likely-to-report-positive-results/ (last visited Apr. 19, 2013) (finding that 85 percent of 
industry-funded studies reported positive outcomes compared to just 50 percent of government-
funded studies). 
 227. Lemmens & Freedman, supra note 51, at 560. 
 228. See Interactions with Pharmaceutical Industry Representatives, AM. MED. ASS’N, 
http://www.ama-assn.org/ama/pub/physician-resources/legal-topics/business-management-topics/ 
interactions-pharmaceutical-industry-representatives.page (last visited Apr. 19, 2013). For 
example, the 2008 Pharmaceutical Research and Manufacturers of American do not allow 
pharmaceutical companies to give doctors non-educational items, such as pens. INSTITUTE OF 
MEDICINE, supra note 218, at 79. The regulations were created in order to enforce the AMA’s 
policy to place the physician-patient relationship ahead of economic self-interest. Ethical 
Guidelines for Gifts to Physicians from Industry, AM. MED. ASS’N, http://www.ama-assn.org/ 
ama/pub/physician-resources/medical-ethics/about-ethics-group/ethics-resource-center/education 
al-resources/guidelines-gifts-physicians.page? (last visited Apr. 19, 2013). 
 229. See Macklin, supra note 23, at 15. 
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review improves the likelihood that the IRB is best performing its role in 
evaluating risks and potential benefits for research subjects.230 
Relationships can also create a separate conflict of interest, in addition to 
the financial conflict of interest, for independent IRBs. For example, the 
Human Investigation Committee IRB that policed the Fabre Research Clinic 
was founded by the same doctor who ran the clinic.231 In 1992, the FDA issued 
a warning letter to the Human Investigation Committee IRB, stating that it had 
a conflict of interest in reviewing studies at the Fabre clinic.232 This same IRB, 
with the same conflict of interest, was overseeing studies at the Fabre clinic 
when a volunteer died in 2002.233 In fact, the FDA had inspected the clinic just 
six days before the volunteer joined the study.234 It was not until nearly thirteen 
years after the FDA first got wind of the conflict of interest issue and after 
human protection failures were found in six inspections235 that the FDA finally 
shut down the Fabre clinic.236 In addition, Miami-based Southern IRB has 
overseen testing at facilities where the husband of the owner of Southern IRB 
is a vice president.237 Most recently, on January 21, 2011, the FDA sent Napoli 
LLC a warning letter because its study investigator, Doctor Kamrava, also sat 
on the IRB that approved his studies.238 These conflicts of interest are unlikely 
to go away because a tremendous amount of money is spent on research and 
development.239 
Both HHS and FDA regulations prohibit an IRB member with a conflict of 
interest from participating in the IRB’s review of the study,240 although what 
constitutes a conflict of interest is undefined.241 However, the regulations are 
 
 230. Id. 
 231. EVANS ET AL., supra note 97, at 14. 
 232. Id. at 4. 
 233. Id. 
 234. Id. 
 235. Id. 
 236. Id. The Human Investigation Committee currently is not registered as an active IRB with 
OHRP. Office for Human Research Protections (OHRP) Database for Registered IORGs & IRBs, 
Approved FWAs, and Documents Received in the Last 60 Days, U.S. DEP’T OF HEALTH AND 
HUMAN SERVS., http://ohrp.cit.nih.gov/search/search.aspx?styp=bsc (last visited Apr. 19, 2013). 
 237. EVANS ET AL., supra note 97, at 2. 
 238. Letter from Steven D. Silverman, Dir., Ctr. for Devices and Radiological Health, to 
Michael M. Kamrava, Chairman, Napoli LLC (Jan. 21, 2011) (on file with the U.S. Dep’t of 
Health and Human Servs.), available at http://www.fda.gov/ICECI/EnforcementActions/Warning 
Letters/2011/ucm240960.htm. 
 239. Ken Gatter, Fixing Cracks: A Discourse Norm to Repair the Crumbling Regulatory 
Structure Supporting Clinical Research and Protecting Human Subjects, 73 U. MO. KANSAS 
CITY L. REV. 581, 584 (2005). 
 240. IRB membership, 45 C.F.R. § 46.107(e) (2011); IRB membership, 21 C.F.R. § 56.107(e) 
(2011). 
 241. Icenogle & Dudek, supra note 96, at 65. 
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silent as to conflicts of interest the IRB has as an entity. Simple reliance upon 
IRB member integrity is not sufficient to address for-profit IRBs’ conflicts of 
interest.242 
In addition to the conflict of interest issues with independent IRBs, a 2011 
study indicates that local IRB members are not fond of central IRBs and that 
the majority of medical school IRB members see no reason to use a central 
IRB.243 IRB members were concerned that moving review away from the site 
of the research study compromises research subjects’ safety because distant 
IRBs may not be able to make informed decisions that local IRBs can make.244 
After the actual protocol review, the second most important element is that the 
reviewers know the researcher’s integrity; local reviewers can have the 
“personal understanding, feel, and flavor that’s needed for a heightened level 
of review.”245 Local review members are committed to the local community, 
and local IRB members do not see for-profit IRBs as having this same 
commitment.246 Additionally, these IRB members were concerned that the 
quality of central IRB reviews can range considerably.247 It is these concerns 
for central IRB quality that create a need for stronger independent IRB 
standards. 
3. OHRP Regulation of IRBs is Insufficient for Research-Subjects’ 
Protection 
“Anyone who can bring together five people, including a community 
representative, a physician, a lawyer, and an ethicist, can set up shop [as an 
IRB] and start competing for business.”248 Although IRB registration is 
required, the federal government does not endorse with registration that the 
registered IRB meets any standards.249 HHS receives three hundred 
applications each month to register IRB boards, a fact which congressmen 
have suggested indicates that there should be concern about people seeing 
 
 242. Lemmens & Freedman, supra note 51, at 558. 
 243. Robert Klitzman, How Local IRBs View Central IRBs in the U.S., 12 BMC MED. ETHICS 
1, 2, 4 (2011). Klitzman conducted two-hour phone interviews with forty-six IRB chairs, 
directors, administrators, and members. Id. at 3. 
 244. Id. at 4, 6. “The farther away you get from the actual group of subjects, the harder it is 
for a committee to judge the risk and benefits . . . . An IRB in another state could not make as 
informed a decision.” Id. at 6. 
 245. Id. at 6 (emphasis removed). 
 246. See id. at 7. 
 247. Klitzman, supra note 243, at 9, 11. 
 248. Emanuel et al., supra note 89, at 942. 
 249. Hearing on IRBs, supra note 1, at 59 (statement of Jerry Menikoff, Dir., Office for 
Human Research Protections, Health and Human Services). 
SAINT LOUIS UNIVERSITY SCHOOL OF LAW 
2013] IS THE CUSTOMER ALWAYS RIGHT? 439 
IRBs as a “quick way to get rich.”250 A group of five people could also create 
an IRB in order to easily approve its own studies, instead of being forced to 
submit protocols to unaffiliated IRBs. 
The same GAO sting operation that caught Coast IRB “rubber-stamping” 
approvals also registered a fake IRB online with HHS and solicited research 
protocols on its website.251 The GAO’s fake IRB’s CEO was Truper Dawg,252 
and the IRB was located in the town of Cheatsville, Arizona.253 HHS registered 
this IRB with no questions asked.254 Additionally, the bogus IRB received 
research protocols from one company because the research coordinator liked 
the IRB’s low price and quick turnaround time.255 This demonstrates that for-
profit IRBs are already enticing researchers to select review based on price and 
time instead of quality of review. Forcing institutions to use an IRB chosen by 
the sponsor, based on price and speed, for review of studies occurring at its 
premises places both research subjects and the quality of research at that 
institution at risk. 
Even with these known risks that for-profit IRBs place on subjects, OHRP 
rarely investigates IRBs.256 In fact, in the past, the FDA has inspected just 1 
percent of study sites.257 The FDA measures compliance by reviewing records 
and consent forms because there currently is no standard to measure the quality 
of IRB decisions.258 IRBs are not required to visit or inspect test centers at any 
time,259 so central IRBs may be clueless as to the ins and outs of the 
institutions with which they are working. Additionally, there are no well-
defined standards for continuing review.260 In fact, one IRB member admitted 
that his continuing review process was complete after he verified that there 
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were no deaths in the study.261 The current status of IRB regulations are in 
trouble and the proposed regulations do nothing to remedy these issues. 
The recent sting operations indicate that independent IRBs may threaten 
the safety of research subjects by “rubber-stamping” protocol approval. 
Without a doubt, however, independent IRBs have a conflict of interest that 
increases the risk of harm to research subjects. The current and the proposed 
regulations regarding independent IRBs are insufficient to ensure research-
subjects’ safety. Above all, there is no evidence that shows research subjects 
will be better protected, or even afforded the same protection given under the 
current regulations, by these proposed regulations. Therefore, the proposed 
regulations should be amended to place an emphasis on research-subjects’ 
protection. 
III.  SUGGESTIONS FOR REGULATIONS IN ORDER TO PRIORITIZE RESEARCH-
SUBJECTS’ PROTECTION 
If forty-four IRBs could not catch a major problem with a study,262 then 
fundamental IRB issues need to be addressed before mandating review be 
moved to a single IRB. It does not make practical sense to take away additional 
eyes of oversight for research-subjects’ protection when IRBs are not 
functioning as they ought to function.263 The IRB system needs help because 
IRBs appear to have a short-term memory when it comes to adverse 
incidents264—IRBs have forgotten incidents, such as Jesse Gelsinger’s death, 
all too quickly.265 Fundamental change is necessary in order to give IRBs the 
capabilities to adequately monitor multi-site research.266 Suggestions for 
change include improving the method by which a sponsor chooses an IRB, 
increasing IRB transparency, enforcing IRB turnaround time restrictions, 
creating standards for measuring and tracking IRB quality, and developing 
avenues of redress for injured research subjects. 
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A drastic option would be to follow the precedent of other countries and 
either ban for-profit IRBs from reviewing studies or have the government 
designate the IRB to review each multi-site study. For example, Switzerland 
banned commercial IRBs in response to an incident similar to the Fabre 
incident in the United States.267 Swiss officials created new regulations 
requiring regulatory approval of IRBs, which resulted in no commercial IRBs 
being approved.268 Similarly, a policy in Alberta, Canada requires all research 
to be reviewed by designated IRBs,269 which takes the power away from the 
sponsor to be able to pick the fastest and cheapest IRB review. Eliminating for-
profit IRBs or changing how sponsors could choose an IRB would help reduce 
the risk to research subjects by ensuring that sponsors cannot pay their way 
into research studies. While banning independent IRBs may not be a popular 
option in the United States, there is support for creating non-profit IRBs to 
review studies.270 If required to use a central IRB, prominent research 
universities and major research sites could band together to place pressure on 
sponsors to select non-profit IRBs for multi-site studies.271 Another option 
would be to have a national board select the IRB to review each study, similar 
to the Canadian policy. The national board could consider IRB expertise and 
quality metrics to select the most appropriate IRB for the respective multi-site 
study. Although both banning for-profit IRBs and requiring that a national 
board select the IRB for each study would require significant changes to the 
current regulations, these suggestions would promote the primary purpose of 
IRBs in protecting research-subjects’ welfare. 
A less radical option would be to propose regulations that increase the 
transparency in the IRB process. Regulations need to control who can create a 
for-profit IRB, and they need to explicitly discuss conflicts of interest and 
interactions with sponsors. The regulations should be written so as to minimize 
the circumstances where reasonable individuals would have reason to question 
whether professional judgment has been improperly influenced, even if it has 
not actually been influenced.272 The regulations should provide research 
subjects more information about the IRB process, since the public interest is 
best served by encouraging transparency and integrity in research.273 
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Transparency would be improved if the consent form disclosed to research 
subjects the IRB name, the IRB’s profit or non-profit status, and the changes, if 
any, that the IRB made to the protocol before approval. Research subjects, as 
well as the research sites, will be better able to assess the risk of undue 
influence on the IRB’s judgment if they are given sufficient information 
regarding the nature, scope, duration, and monetary value of the IRB’s 
relationship with the study sponsor.274 
This transparency will help improve volunteer trust in medical research.275 
Research subjects currently have no assurances that an IRB places their 
welfare as its highest priority, since these for-profit companies can hide behind 
the walls of secrecy.276 All states should enact a law, following Maryland’s 
lead, requiring IRBs to make all meeting minutes available to the public. This 
disclosure and improved transparency could provide incentives for sponsors to 
choose reputable IRBs. 
Regulations should also set review time minimums so that independent 
IRBs can no longer advertise or compete on the speed of review. Since recent 
IRB failures have been linked to IRB time constraints,277 time-pressured 
reviews should be avoided whenever possible. The regulations need to set 
minimum turnaround times for IRB review, which would help ensure that 
independent IRBs are not squeezing the reviews into short turnaround times in 
order to compete for business.278 Forty-eight hour guarantees, like the one the 
Essex IRB promises on its website,279 should not be allowed. Reducing the 
ability for independent IRBs to compete on review time will improve research-
subjects’ protection. 
In addition, HHS should create standards by which to evaluate IRB quality, 
and then the agencies should rely on this quality data before creating new 
regulations. Simply relying on public comment does not provide the same kind 
of support as factual data, especially when considering that the lives and well-
being of research subjects are at stake. The agencies could require independent 
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IRBs to be accredited through institutions like the Association for the 
Accreditation of Human Research Protections Programs (AAHRPP).280 
However, since none of the accreditation standards are revolutionary, it is 
unknown whether accreditation will solve the issues with IRBs.281 Before 
mandating a central IRB, HHS should review data from the NCI and other 
recent recommendations. For example, in September 2011, President Obama 
ordered the Presidential Commission for the Study of Bioethical issues to 
review research-subjects’ protection.282 Additionally, the Secretary’s Advisory 
Committee on Human Research Protections recommended that a single federal 
agency review all research, regardless of whether it involves federal funding or 
is an FDA-regulated product, and that uniform standards for managing 
conflicts of interests be created.283 Research subjects will be better protected 
with a research protocol overhaul rather than the quick-fix “protections” these 
proposed regulations provide. 
Regulations focusing on improving IRBs are vital to the protection of 
research subjects; however, legal remedies for injured research subjects should 
also be addressed in the new regulations. The current regulations provide no 
legal remedies or redress for research-subjects’ injuries.284 While institutions 
or IRBs may be able to require study sponsors to indemnify them for 
negligence in research studies,285 research subjects do not have a similar 
redress for their injuries. Research subjects, as a practical matter, are unable to 
contract with the study sponsors for help when something goes awry in a 
study.286 IRBs should be held legally responsible when they play a role in a 
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subject’s injury.287 The public health is not served when IRBs, especially for-
profit IRBs, can escape the consequences of misconduct.288 Research studies 
advance public health by improving options for treatment of diseases, but there 
can be no scientific progress in clinical trials without volunteer subjects. The 
public health benefits when volunteers trust the research system. However, 
volunteer subjects will lose confidence in the system if for-profit IRBs cannot 
be held liable for decisions that cause injuries. A benefit of turning to the legal 
system is that it adds no bureaucracy to the regulated environment.289 If HHS 
wants to outsource ethical reviews to for-profit companies, research subjects 
should be provided an easier way to be compensated from the IRBs that fail to 
protect them. 
Proposed regulations simply cannot rely on just the goodwill of IRB 
members—research subjects require more than goodwill to be protected from 
the risks of clinical trials.290 Quality IRB reviews depend on an effective 
protocol process review,291 and new proposed regulations are necessary in 
order to effectively protect research subjects. 
CONCLUSION 
HHS designed IRBs for the primary purpose of protecting human subjects 
volunteering in research studies.292 These volunteers put their lives at risk in 
clinical trials, which may be of no benefit to them.293 At a minimum, the public 
owes these volunteers the dignity of having someone look out for their best 
interests. Regulations that will push more research review into the hands of 
for-profit IRBs without any additional oversight does not give these research 
subjects the protection they deserve. Central IRBs might be the solution for 
multi-site trials, but only with additional regulations that adequately protect 
research subjects, not with the present regulations that serve research integrity 
interests rather than individual safety interests. 
When one out of three IRBs tested in a sting operation was found to have 
“rubber-stamped” a protocol’s approval,294 it raises concerns about all other 
IRBs. Catching Essex IRB in a similar sting two years later demands action 
from HHS. IRB reform is necessary to improve the protection of research 
subjects. If HHS wants to mandate the use of central IRBs, at a minimum the 
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regulations should provide standards for measuring IRB quality, increased 
transparency, stronger regulation of independent IRBs, and an avenue of 
redress for injured subjects. There is injustice in leaving research subjects 
without redress when the companies profiting from their protocol review fail to 
protect them. 
Protecting research subjects does not require that research efforts take a 
backseat to the research-subjects’ interests, it simply requires that the research 
subjects’ safety be placed ahead of financial interests.295 
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